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Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in car-
diac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that
recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxida-
tive phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was
administered by sub-cutaneous injection over 8weeks with oral iron (100mg) supplemen-
tation taken daily. Mitochondrial OXPHOSwas quantiﬁed by high-resolution respirometry in
saponin-permeabilized muscle ﬁbers obtained from biopsies of the vastus lateralis before
and after rhEpo treatment. OXPHOSwas determinedwith themitochondrial complex I sub-
strates malate, glutamate, pyruvate, and complex II substrate succinate in the presence
of saturating ADP concentrations, while maximal electron transport capacity (ETS) was
assessed by addition of an uncoupler. rhEpo treatment increased OXPHOS (from 92± 5 to
113± 7 pmol·s−1·mg−1) and ETS (107± 4 to 143± 14 pmol·s−1·mg−1, p< 0.05), demon-
strating that Epo treatment induces an upregulation of OXPHOS and ETS in human skeletal
muscle.
Keywords: mitochondria, oxidative phosphorylation, rhEPO, muscle, humans
INTRODUCTION
Erythropoiesis is regulated through activation of the erythropoi-
etin (Epo) receptor (Epo-R) present on erythroid progenitor cells
stimulating growth and differentiation of the red blood cell pre-
cursors (Jelkmann, 1992). In addition to this, Epo also suppresses
plasma volume and thereby effectively controls arterial content
(Lundby et al., 2007; Olsen et al., 2011). Epo-R have been observed
in several non-hematopoietic tissues and cells such as the liver,
pancreas, heart, uterus, central nervous system, vascular endothe-
lium, satellite cells, and skeletal muscle (Farrell and Lee, 2004;
Lundby et al., 2008a; Rundqvist et al., 2009; Carraway et al., 2010).
The functionality of the Epo-R in mediating the effect of Epo in
non-hematopoietic cells is currently debated (Sinclair et al., 2010),
however Epo treatment in the mouse has been found to induce
mitochondrial biogenesis in cardiac and skeletal muscle accompa-
nied by an increase in state 3 mitochondrial respiratory capacity
(Carraway et al., 2010). Consistent with this pattern, mice electro-
transfected with Epo gain less body fat when on a high fat diet
as compared to matched control mice (Hojman et al., 2009), and
there is some evidence for a shift in skeletal muscle ﬁber type in
mice with Epo treatment (Cayla et al., 2008). In humans no effect
on skeletal muscle capillarization, ﬁber type (Lundby et al., 2008a),
and myoglobin (Robach et al., 2009) have been found with rhEpo
treatment. Yet, the ﬁnding that recombinant human Epo (rhEpo)
enhances submaximal endurance performance to a greater extent
(∼54%) thanwhat canbe accounted for by increased bloodoxygen
carrying capacity (∼12%), and that lactate is lower at a simi-
lar relative submaximal exercise intensity after rhEpo treatment
(Thomsen et al., 2007), suggests an additional effect of rhEpo at
the metabolic level. The purpose of the present study was hence
to test the hypothesis that rhEpo treatment leads to enhanced
skeletal muscle mitochondrial oxidative phosphorylation capacity
(OXPHOS) in humans.
MATERIALS AND METHODS
SUBJECTS
Six healthy young men aged 21± 2 years, height 180± 1 cm,
weight 73± 2 kg, volunteered to participate in the study. None
of the volunteers had been exposed to rhEpo previously. All sub-
jects agreed to maintain their level of physical activity unchanged
throughout the trial period. Activity level was monitored through-
out the study period with a heart rate monitor (Polar Electro,
Finland) worn at all hours of the day except when sleeping.
Subjects were informed about the possible risks and discomfort
involved before giving their written consent to participate. The
study was carried out according to the Declaration of Helsinki
and was approved by the Ethical committee of Copenhagen
(H-2-2010-104).
RECOMBINANT HUMAN EPO TREATMENT
The rhEpo treatment aimed to increase the hematocrit (Hct) to
∼50% and to maintain that value throughout the study period.
The value of 50% was chosen, partly from a health perspective
to minimize the risk of thrombosis and partly because it is the
maximum allowed value in many sports. We treated the subjects
with the following regime: 1 week of daily sub-cutaneous (SC)
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injections of 5000 IU of rhEpo (NeoRecormon Roche, Schweiz),
followed by 1 week without treatment. Thereafter the subjects
were given one weekly SC injection for 7 weeks, titrating the
rhEpo dosage (Figure 1) depending on their Hct level (giving
either 0, 2500, or 5000 IU). The subjects were instructed to take
daily iron supplements of 100 mg throughout the study period,
starting 2 weeks prior to the rhEpo treatment. Venous blood was
drawn to assess blood hematocrit (Radiometer, ABL 800, Den-
mark) weekly to monitor the Hct value over the course of rhEpo
treatment.
PEAK OXYGEN CONSUMPTION
Expired minute ventilation, O2 fraction, and pulmonary VO2
were measured continuously using an automated metabolic cart
(Oxycon Pro, Jaeger,Germany). Subjects performed exercise on an
electrically braked cycle ergometer (Ergometrics 800, Jaeger, Ger-
many). The exercise protocol began with a 6-min warm up period
at 60W followed by incremental increases in workload by 35W
each minute until exhaustion.
BODY COMPOSITION (DXA)
Dual X-ray absorptiometry (DXA) scans were performed before
and after the study period for determination of percentage of body
fat and lean body mass (Lunar, Madison, WI, USA). Fat free mass
and fat mass were expressed as absolute values.
SKELETAL MUSCLE BIOPSIES
A muscle biopsy was taken prior to the 8 weeks of rhEpo treatment
andagain 1 week after the treatmentperiod ended.After local anes-
thesia (1% lidocaine) of the skin and superﬁcial muscle fascia, the
biopsy was obtained from the vastus lateralis muscle using the
Bergstrøm method. A portion of the obtained muscle tissue was
frozen immediately in liquid nitrogen and stored at−80˚C for later
analysis of citrate synthase (CS) as a mitochondrial matrix marker
reﬂecting mitochondrial content. A small portion of the biopsied
muscle was placed in relaxing medium (10 mM Ca-EGTA buffer,
0.1μM free calcium, 20 mM imidazole, 20 mM taurine, 50 mM
FIGURE 1 | Blood hematocrit (%) and rhEPO dosage over the 8week
treatment period. Data are means±SEM. Asterisk ∗ indicates signiﬁcant
difference pre vs. post, p<0.05.
K-MES, 0.5 mM DTT, 6.5 mM MgCl2, 5.8 mM ATP, 15 mM phos-
phocreatine, pH 7.1) at 2–4˚C. Individual ﬁber bundles were then
separated with forceps to achieve a high degree of ﬁber separation.
The ﬁber bundles were then permeabilized for 30 min in 3 ml
of ice-cold relaxing medium with saponin (50μg·ml−1). After
chemical permeabilization, the tissue was rinsed twice for 10 min
in chilled solution of EGTA (0.5 mM), MgCl2·6H2O (3 mM),
K-lactobionate (60 mM), Taurine (20 mM), KH2PO4 (10 mM),
HEPES (20 mM), sucrose (110 mM), BSA (1 g/l), at pH 7.1. The
muscle bundleswere then blotted andmeasured forwetweight in a
precision balance. The muscle ﬁbers were then transferred imme-
diately into the respirometer (Oxygraph-2k, Oroboros Instru-
ments, Austria) containing respirometry medium at ambient air
saturation at a chamber temperature of 37˚C.
RESPIROMETRY
Standardized instrumental and chemical calibrations were under-
taken on the Oxygraph-2k high-resolution respirometer and
applied to correct for back-diffusion of oxygen into the cham-
ber, leak from the exterior, oxygen consumption by the chemical
medium and O2 sensor. O2 ﬂux was resolved by software (Dat-
Lab 4, Oroboros Instruments, Austria) that calculates non-linear
changes in thenegative timederivative of the oxygen concentration
signal.
All muscle respirometry measurements were done in dupli-
cate. Oxygen diffusion limitation of respiration was prevented by
maintaining oxygen levels in the respirometer above air satura-
tion (450–300 nM range). A substrate-inhibitor titration protocol
was applied as follows. Routine respiration (state 2; absence of
adenylates) with electron supply of NADH to Complex I was
assessed by addition of malate (2 mmol·l−1), followed by titra-
tion of pyruvate (10 mmol·l−1), and glutamate (10 mmol·l−1).
Coupled state 3 respiration of Complex I was achieved by addi-
tion of saturating adenosine-di-phosphate (ADP 5 mmol·l−1).
Addition of succinate (10 mmol·l−1) then stimulated respira-
tion further through convergent electron input by FADH2 to
the Q-junction through complex II to achieve maximal coupled
respiration (OXPHOS). Intactness of the outer mitochondrial
membrane was tested by quantifying respiration after titration
of cytochrome c (10μmol·l−1). Uncoupled respiration and max-
imal electron transport capacity (ETS) was assessed by addition
of carbonyl cyanide-p-triﬂuoromethoxyphenylhydrazone (FCCP)
in steps of 0.25 mM. The isolated activity of cytochrome oxidase
(COX) was measured by addition of N,N,N′,N′-tetramethyl-1,4-
benzenediamine, dihydrochloride (TMPD 500μM)+ ascorbate
(2 mM) after antimycin A (2.5μM).
CITRATE SYNTHASE ACTIVITY
Skeletal muscle tissue was freeze-dried and dissected free of all
visible blood, adipose, and connective tissue under a stereomicro-
scope. Approximately 2 mg of the dissected tissue was homoge-
nized (TissueLyser II,Qiagen,Germany) in 800μl 0.3 MK2 HPO4,
0.05% BSA, pH 7.7. Spectrometric determination of CS activity
was performed at 25˚C by 50 times dilution in a solution contain-
ing 100μM acetyl-CoA, 0.5 mM NAD (free acid), 1 mM sodium
malate, 8μg ml-1 malate dehydrogenase (1200 U mg-1, Boehringer
Germany), 2.5 mM EDTA, 10 mM Tris–HCl (pH 8.0).
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DATA ANALYSIS
To analyze regulatory characteristics of speciﬁc branches of the
ETS, several ratio comparisons were made. Physiological Com-
plex I+ II substrate combinations support maximum ETS and
OXPHOS capacities due to the additive effect of multiple electron
supply pathways converging at the Q-junction. The substrate con-
trol ratio (SCR) calculated as the ratio of Complex I to Complex
I+ II respiratory rate (GMP3/GMPS3) was determined for analy-
sis of the substrate limitation of complex I respiration to maximal
coupledmitochondrial respiration.Thenon-coupled state of max-
imum respiration (E) was experimentally induced by titration of
the uncoupler FCCP to collapse the proton gradient across the
mitochondrial inner membrane and thus to measure the capacity
of the ETS in the open-circuit operation of respiration. The ratio
P/E indicates the extent of limitation of ETS by the phospho-
rylation system, where a ratio of 1.0 indicates no limitation. The
isolated activity of COX measured with ascorbate and TMPD after
ETS inhibition by antimycin A was taken as a functional measure
of COX enzyme activity in the intact system. All values are given
as means± SEM for all experiments. A one-way ANOVA was used
to detect differences over time during the Epo treatment period.
Paired t -tests were used to determine differences in mitochondr-
ial OXPHOS and ETS capacity pre–post Epo treatment. For all
evaluations, a p value of <0.05 was considered signiﬁcant.
RESULTS
BLOOD AND EXERCISE RESPONSES
The mean Hct of the six subjects before rhEpo treatment was
45.7± 0.5%, increasing to 48.3± 0.8% within 1 week with the
35000 IU dose of rhEpo. After the 8 week intervention period,
the mean Hct for the whole group was increased signiﬁcantly
to 51± 1% (Figure 1). Three of the six subjects received full
treatment dosage with a total of 70.000 IU rhEpo over 8 weeks,
while two subjects were administered 67.500 and 62.500 IU,
respectively. The remaining subject exhibited a strong response
to the rhEpo injections, and received a total of 50.000 IU. Epo
treatment increased VO2 max by 8.3± 2% from 54± 3 to
58± 3 ml·kg−1·min−1 (Table 1). Body composition expressed as
BMI and body fat% was unchanged by rhEpo treatment (Table 1).
Compliance to stable activity level during the treatment periodwas
reﬂected in stable daily and weekly average HR, results not shown.
MITOCHONDRIAL FUNCTION
After Epo treatment state 3 respiration with Complex I sub-
strates (MPG3) was 52± 5 before and 64± 7 pmol·s−1·mg·1
Table 1 | Subject characteristics at baseline and after 8weeks of rhEpo
treatment.
Pre Post
Weight (kg) 73±2 73±2
BMI 23±1 22±1
Body fat (%) 19±2 17±3
VO2 max (ml·kg−1·min−1) 54±3 58±3*
Data are means±SEM.
*Indicates signiﬁcant difference pre vs post.
after rhEpo while respiratory rate for convergent electron sup-
ply through the Q-junction for Complex I + II (Figure 2)
increased from 92± 6 to 113± 7 pmol·s−1·mg−1. The substrate
control ratio (MPG3/MPGS3) was unchanged (0.56± 0.04 vs.
0.56± 0.03) by Epo treatment (Table 2), while the maximal
ETS measured with FCCP titration increased from 107± 4 to
143± 13 pmol·s−1·mg−1. The coupling (phosphorylation) con-
trol ratio (P/E) reﬂecting the ratio of OXPHOS to ETS was
unchanged (from 0.87± 0.04 to 0.83± 0.03), indicating similar
control of ETS capacity by the OXPHOS system (Table 2). Some
of the samples were excluded from statistical analysis due to a high
stimulation of respiration by addition of cytochrome c. In the
baseline experiments one sample showed an increase of respiration
of 26%and in the post Epo experiments 2 samples in different sub-
jects were excluded with responses of 40 and 60% respectively. For
these subjects a single respirometric measurement was used in the
analysis. The isolated activity of COX was similar before and after
(333± 25 vs. 320± 20 pmol·s−1·mg−1) Epo treatment, as was CS
activity (129± 10 vs. 139± 13μmol·g−1·min−1, p = 0.06).
DISCUSSION
The main ﬁnding in this study is that rhEpo treatment in humans
increased skeletal muscle mitochondrial respiratory capacity.
OXPHOS capacity with substrates providing electrons to complex
I and II of the electron transport chain was elevated by 22% with
rhEPO treatment (Figure 2). All subjects exhibited an increase in
OXPHOSwith Epowhich represents themaximalADP-stimulated
oxygen consumption linked to the formation of ATP. The increase
in whole body VO2 peak (8%) was similar to the increase in blood
hematocrit (12%) as found previously (Lundby et al., 2008b),
but much smaller than the increase in muscle oxidative capacity.
FIGURE 2 | Mitochondrial respiration measured by high-resolution
respirometry in permeabilized fibers from the vastus lateralis before
and after Epo treatment. OXPHOS; state 3 respiration for Complex I+ II
before and after rhEpo. ETS; Maximal ElectronTransfer System assessed
adding FCCP before and after rhEPO treatment. Data are means±SEM.
Asterisk ∗ indicates signiﬁcant difference pre vs. post, p<0.05.
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Table 2 | Mitochondrial flux control ratios before and after rhEpo
treatment.
Pre Post
MPG3/MPGS3 0.56±0.04 0.56±0.03
P /E 0.87±0.04 0.83±0.03
P/CS 0.73±0.07 0.83±0.06
P/COX 0.28±0.01 0.38±0.04*
E/COX 0.33±0.02 0.45±0.06*
MPG3/MPGS3 (M, malate, P, pyruvate, G, glutamate, S, succinate, 3=ADP)
= substrate control ratio for Complex I: Complex I+ II respiration; P/E=
phosphorylation control ratio indicating the ratio of state 3 respiration to
maximal electron transport capacity determined by addition of the uncoupler
FCCP; P/CS=OXPHOS relative to citrate synthase activity; COX= isolated Vmax
of cytochrome oxidase measured in the presence of TMPD+ ascorbate and
Antimycin A; P/COX= the ratio of coupled state 3 respiration to COX activity;
E/COX= the ratio of ETS to COX activity. Data are means±SEM.
*Indicates signiﬁcant difference pre vs post.
This ﬁnding is consistent with the concept that humans have
an excess capacity of muscle mitochondria over O2 delivery due
to limits of cardiac output during whole body exercise (Boushel
et al., 2011). In that study peak VO2, cardiac output, limb blood
ﬂow, a-v femoral blood gases, O2 diffusion capacity and muscle
mitochondrial capacity were measured. For O2 delivery to match
muscle mitochondrial capacity during cycling exercise a blood
ﬂow increase of ∼8l min−1 at peak exercise would be required.
The ﬁnding of a 22% increase in mitochondrial OXPHOS in the
present study indicates that the disparity between O2 delivery and
muscle oxidative capacity is even larger with Epo treatment, and
the proportional increase in hematocrit and whole body VO2
emphasizes the large dependence on O2 delivery.
Thenon-coupled state of maximumrespirationwas experimen-
tally induced by titration of the uncoupler FCCP for measurement
of the capacity of the ETS, and this O2 ﬂux rate was also increased
after rhEpo treatment. Proportional enhancement of theOXPHOS
system was reﬂected in a similar ratio of Complex I vs. com-
plex I+ II respiration (MPG3/MPGS3; Table 2). These ﬁndings
are consistent with the higher mitochondrial respiratory capacity
reported in cardiac muscle of mice (Carraway et al., 2010). That
study demonstrated that Epo treatment activates the JAK/STAT,
protein kinase B, and eNOS pathways, leading to upregulation
of nuclear respiratory factor-1, peroxisome proliferator-activated
receptor-coactivator 1 and mitochondrial transcription factor-A
gene expression. The Epo-R was required for this response, since
Epo-R silencing in cardiomyocytes blocked the Epo-mediated
nuclear translocation of nuclear respiratory factor-1. A similar
but modest activation of the JAK/STAT pathway by Epo has been
demonstrated in human skeletal muscle following acute exercise
(Rundqvist et al., 2009).
We measured the isolated activity of COX as an indepen-
dent measure of mitochondrial functionality by titrating the
redox substrates ascorbate and TMPD following inhibition of
the respiratory chain upstream at Complex III with Antimycin
A. We found no change in COX activity with rhEpo treatment.
Relative to the changes in OXPHOS and ETS, this indicates
qualitative changes in mitochondrial function. Traditionally it
has been thought that increases in mitochondrial respiratory
capacity result from an enlargement of mitochondrial volume
rather than by altered intrinsic capacity of mitochondria (Hol-
loszy, 1967; Reichmann et al., 1985; Tonkonogi and Sahlin, 1997;
Tonkonogi et al., 1997, 2000). A generally held view is that
mitochondrial respiratory capacity is relatively constant at ∼5 ml
O2 per milliliter of cristae volume (Schwerzmann et al., 1989).
However, more recent studies have shown that different lifestyle
inﬂuences such as acute exercise (Fernström et al., 2004) and
high fat diet (Anderson et al., 2009; Skovbro et al., 2011) may
change the qualitative properties of mitochondria. This has also
been shown in pathological conditions such as type 2 diabetes
(Mogensen et al., 2007; Phielix et al., 2008) and chronic obstruc-
tive lung disease (Naimi et al., 2011). The intrinsic properties
of the mitochondrion are usually determined by relating respi-
ration rate to a measure of mitochondrial content. Five of the
six subjects showed an increase in CS activity but statistical sig-
niﬁcance was not reached (p = 0.06). This likely reﬂects a type
2 error due to the small number of subjects. While mitochon-
drial volume may also be increased by rhEpo treatment, several
independent measures indicate that mitochondrial capacity can
be up-regulated independent of changes in mitochondrial vol-
ume. The ratios of OXPHOS (P/COX) and ETS (E/COX) to COX
activity were signiﬁcantly elevated, and the OXPHOS capacity
expressed per CS activity showed the same directional pattern
(0.84± 0.06 vs. 0.73± 0.07, p = 0.07) following rhEpo treatment
(Table 2) suggesting a higher mitochondrial respiratory capacity
per mitochondria.
In summary, the present results demonstrate that rhEpo treat-
ment induces increases in both blood hematocrit and skeletal
muscle mitochondrial respiratory capacity in humans. Propor-
tional increases in OXPHOS with complex I and I+ II substrates
were found along with a higher electron transport capacity. The
present ﬁndings extend on previous studies in rodents to demon-
strate an upregulation of human skeletal muscle mitochondrial
capacity after rhEpo treatment. The ﬁndings may have clinical
implications for patients with impaired cardiovascular and muscle
metabolic disorders.
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